statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Tuesday, August 6, 2024, after the close of the U.S. financial markets. Acadias...

Clinical Data from Open-Label Extension LILAC-1 and LILAC-2 Studies Evaluating Long-Term Safety and Efficacy of DAYBUE (trofinetide) in Patients with Rett Syndrome Published in Med

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from two open-label extension studies, LILAC-1 and LILAC-2, which showed that patients treated with...

Acadia Pharmaceuticals Presents DAYBUE (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting

Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS study will be presented at the 2024 International Rett Syndrome Foundation (IRSF...

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on May 15, 2024, the Compensation Committee of Acadias Board of Directors (the Committee) granted inducement awards consisting of...

Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of Magnolias Guide to Adventuring, a new, 10-part, documentary video series by award-winning TV producer, AJ Tesler, and his...

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: Citizens JMP Life Sciences Conference Fireside Chat: Tuesday, May 14, 2024...

Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2024. In the first quarter of 2024, Acadia delivered net product sales of $205.8...

Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has awarded 10 academic scholarships to eligible recipients of the first Rett Sibling Scholarship. The Rett Sibling Scholarship...

Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 10, 2024, the Compensation Committee of Acadias Board of Directors (the Committee) granted inducement awards consisting of...

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Volume	2.36M
52-Wk High	$32.59
52-Wk Low	$14.55

ACAD Acadia Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals